Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Alzheimer's Disease

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

The new 360 mg weekly autoinjector lets eligible patients continue therapy after 18 months of infusions with comparable benefits and safety.

Stories older than 24h

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

NICE Bars New Alzheimer’s Antibodies from NHS Over Cost and Capacity

NICE Poised to Reject NHS Coverage for Breakthrough Alzheimer’s Drugs

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

EU Approves First Alzheimer's Drug Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs